Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - The PCPT risk calculator has been proposed as a means to improve upon the limitations of PSA in selecting men for prostate biopsy. The authors of this study sought to compare the performance of the PCPT risk calculator with multiparametic MRI (MP-MRI) in classifying men at risk for prostate cancer. auaMen with an abnormal PSA or DRE, as well as a suspicious lesions identified on MP-MRI, were prospectively enrolled. Three radiologists reviewed the images and graded the lesions on a 5-point Likert scale. An MR/TRUS fusion guided biopsy, as well as a standard 12-core systematic biopsy, was then performed and pathology reviewed by a single pathologist.

The authors determined the AUC for the PCPT risk calculator predicted risk of any prostate cancer was 0.67. The sensitivity, specificity, and false positive rate of the PCPT risk calculator with a cutoff of 30% as proposed by Nam et al (JCO, 2011) were 98.9%, 0% and 34.8%, respectively. The AUC for predicted risk of aggressive disease was 0.68. This was compared to the AUC of MP-MRI for predicting any prostate cancer and aggressive disease, as 0.76 and 0.84, respectively.

MP-MRI seemed to significantly outperform the PCPT risk calculator in selecting men for prostate biopsy. The authors point out that the MP-MRI also provides staging information and risk stratification that can be used to guide treatment. Despite the findings in an optimized patient cohort, the study reveals than the integration of MP-MRI into a patient risk assessment can be yet another adjunct to treatment planning based on recent advances in preoperative imaging.

Presented by Simpa Salami at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

New Hyde Park, NY USA

Written by Jason T. Rothwax, National Cancer Institute

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 3

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting